4D Molecular Therapeutics, Inc. SEC filings FDMT

4D Molecular Therapeutics, Inc. has 439 filings in SEC EDGAR's recent list, going back to Aug 13, 2015. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 28, 2026 (other events). The company's fiscal year ends on December 31.

Form Description Filed Period
ARS Annual report to shareholders Apr 28, 2026 Dec 31, 2025
10-K Annual report Mar 18, 2026 Dec 31, 2025
ARS Annual report to shareholders Apr 29, 2025 Dec 31, 2024
10-K Annual report Feb 28, 2025 Dec 31, 2024
ARS Annual report to shareholders Apr 10, 2024 Dec 31, 2023
10-K Annual report Feb 29, 2024 Dec 31, 2023
10-K Annual report Mar 15, 2023 Dec 31, 2022
10-K Annual report Mar 28, 2022 Dec 31, 2021
10-K Annual report Mar 25, 2021 Dec 31, 2020

Showing 9 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
FDMT (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Emeryville, CA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1650648
Former names
4D Molecular Therapeutics Inc. (until May 12, 2022); 4D Molecular Therapeutics Inc (until Sep 30, 2019)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.